Kazia Therapeutics Ltd (ASX:KZA) shares fell 0.8% during mid-day trading on Friday . The stock traded as low as A$0.59 ($0.42) and last traded at A$0.59 ($0.42), 10,650 shares were traded during mid-day trading. The stock had previously closed at A$0.60 ($0.42).
The company has a 50-day simple moving average of A$0.61 and a 200-day simple moving average of A$0.50. The stock has a market cap of $36.68 million and a P/E ratio of -3.30.
Kazia Therapeutics Company Profile (ASX:KZA)
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer.
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.